Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD9008 Drug-Drug Interaction Study with Itraconazole and Carbamazepine
NCT05418582Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jan 2022
- Primary completion
- Jun 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of sunvozertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 11 days, Time to Maximum Plasma Concentration at 11 days and 2 more. Started Jan 2022; status: completed.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05418582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418582.